Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 343, doi. 10.1007/s00262-011-1110-7
- By:
- Publication type:
- Article
Works matching IS 03407004 AND DT 2012 AND VI 61 AND IP 3
Results: 16
1
2
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 353, doi. 10.1007/s00262-011-1106-3
- By:
- Publication type:
- Article
3
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 373, doi. 10.1007/s00262-011-1100-9
- By:
- Publication type:
- Article
4
Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 323, doi. 10.1007/s00262-011-1105-4
- By:
- Publication type:
- Article
5
Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 335, doi. 10.1007/s00262-011-1108-1
- By:
- Publication type:
- Article
6
SCF and TLR4 ligand cooperate to augment the tumor-promoting potential of mast cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 303, doi. 10.1007/s00262-011-1098-z
- By:
- Publication type:
- Article
7
Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 313, doi. 10.1007/s00262-011-1099-y
- By:
- Publication type:
- Article
8
Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 385, doi. 10.1007/s00262-011-1111-6
- By:
- Publication type:
- Article
9
Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 409, doi. 10.1007/s00262-011-1112-5
- By:
- Publication type:
- Article
10
In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 363, doi. 10.1007/s00262-011-1107-2
- By:
- Publication type:
- Article
11
Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/ neu-tolerant mice.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 397, doi. 10.1007/s00262-011-1113-4
- By:
- Publication type:
- Article
12
Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 3, p. 425, doi. 10.1007/s00262-011-1188-y
- By:
- Publication type:
- Article
13
Response to the rebuttal letter of Kountouras and colleagues regarding the paper by Codolo et al. 'HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response'.
- Published in:
- 2012
- By:
- Publication type:
- Letter
14
A rebuttal to the potential anti-tumour benefit of Helicobacter pylori-induced neutrophil-activating protein.
- Published in:
- 2012
- By:
- Publication type:
- Letter
15
HP-NAP new therapy for bladder cancer: numquam periculum sine periculo vincitur.
- Published in:
- 2012
- By:
- Publication type:
- Letter
16
Advances in cellular therapy: 6th international symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany.
- Published in:
- 2012
- By:
- Publication type:
- Report